Q3 EPS Forecast for Adherex Technologies Reduced by Analyst

Adherex Technologies Inc. (NASDAQ:FENC) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Adherex Technologies in a report released on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.06 per share for the quarter, down from their prior estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is $0.29 per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2026 earnings at $0.09 EPS, FY2026 earnings at $0.21 EPS, Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.19 EPS and FY2027 earnings at $0.87 EPS.

Adherex Technologies (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The business had revenue of $17.87 million for the quarter, compared to analyst estimates of $16.21 million. Adherex Technologies had a negative net margin of 6.09% and a negative return on equity of 5.71%.

A number of other research analysts have also weighed in on FENC. Wall Street Zen raised Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adherex Technologies in a report on Friday, July 17th. Wedbush increased their target price on Adherex Technologies from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 12th. B. Riley Financial reiterated a “buy” rating and set a $18.00 target price (up from $16.00) on shares of Adherex Technologies in a research note on Wednesday, August 12th. Finally, Zacks Research upgraded Adherex Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Adherex Technologies Stock Performance

FENC stock opened at $11.65 on Thursday. The firm has a 50 day moving average price of $11.09 and a 200-day moving average price of $9.13. Adherex Technologies has a 52-week low of $5.65 and a 52-week high of $13.25. The firm has a market capitalization of $408.45 million, a price-to-earnings ratio of -89.62 and a beta of 1.10.

Insiders Place Their Bets

In other news, CFO Robert Andrade sold 75,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer owned 217,675 shares of the company’s stock, valued at $2,564,211.50. This trade represents a 25.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of Adherex Technologies stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $12.18, for a total transaction of $146,160.00. Following the transaction, the insider directly owned 9,519 shares in the company, valued at $115,941.42. This represents a 55.76% decrease in their position. The SEC filing for this sale provides additional information. 10.73% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Adherex Technologies

A hedge fund recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC bought a new position in shares of Adherex Technologies Inc. (NASDAQ:FENC) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 10,897 shares of the company’s stock, valued at approximately $66,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.